Syros Pharmaceuticals (SYRS) Competitors $0.0026 -0.03 (-91.33%) As of 07/15/2025 03:41 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SYRS vs. PBM, SPRB, AFMD, PRFX, JAGX, ADTX, ONCO, PTN, AWH, and ALZNShould you be buying Syros Pharmaceuticals stock or one of its competitors? The main competitors of Syros Pharmaceuticals include Psyence Biomedical (PBM), Spruce Biosciences (SPRB), Affimed (AFMD), PainReform (PRFX), Jaguar Animal Health (JAGX), Aditxt (ADTX), Onconetix (ONCO), Palatin Technologies (PTN), Aspira Women's Health (AWH), and Alzamend Neuro (ALZN). These companies are all part of the "pharmaceutical products" industry. Syros Pharmaceuticals vs. Its Competitors Psyence Biomedical Spruce Biosciences Affimed PainReform Jaguar Animal Health Aditxt Onconetix Palatin Technologies Aspira Women's Health Alzamend Neuro Psyence Biomedical (NASDAQ:PBM) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings. Which has more risk and volatility, PBM or SYRS? Psyence Biomedical has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500. Comparatively, Syros Pharmaceuticals has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500. Is PBM or SYRS more profitable? Psyence Biomedical's return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Psyence BiomedicalN/A N/A N/A Syros Pharmaceuticals N/A -3,369.56%-97.04% Do analysts rate PBM or SYRS? Syros Pharmaceuticals has a consensus target price of $3.33, indicating a potential upside of 128,105.13%. Given Syros Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Syros Pharmaceuticals is more favorable than Psyence Biomedical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Psyence Biomedical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Syros Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20 Does the media prefer PBM or SYRS? In the previous week, Psyence Biomedical had 1 more articles in the media than Syros Pharmaceuticals. MarketBeat recorded 1 mentions for Psyence Biomedical and 0 mentions for Syros Pharmaceuticals. Psyence Biomedical's average media sentiment score of 1.89 beat Syros Pharmaceuticals' score of 0.00 indicating that Psyence Biomedical is being referred to more favorably in the media. Company Overall Sentiment Psyence Biomedical Very Positive Syros Pharmaceuticals Neutral Which has higher earnings & valuation, PBM or SYRS? Psyence Biomedical has higher earnings, but lower revenue than Syros Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPsyence BiomedicalN/AN/A$1.01MN/AN/ASyros Pharmaceuticals$386K0.18-$164.57M-$3.030.00 Do insiders and institutionals believe in PBM or SYRS? 77.4% of Psyence Biomedical shares are owned by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are owned by institutional investors. 3.6% of Psyence Biomedical shares are owned by company insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummarySyros Pharmaceuticals beats Psyence Biomedical on 7 of the 12 factors compared between the two stocks. Get Syros Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SYRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SYRS vs. The Competition Export to ExcelMetricSyros PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.65M$724.83M$5.61B$9.29BDividend YieldN/A4.84%4.23%4.03%P/E Ratio0.001.1828.5419.58Price / Sales0.1825.52430.1194.56Price / CashN/A19.5636.0257.93Price / Book0.006.918.145.54Net Income-$164.57M-$4.17M$3.24B$257.73M7 Day PerformanceN/A1.41%0.17%-0.08%1 Month PerformanceN/A1.34%5.95%8.09%1 Year PerformanceN/A7.45%26.22%13.02% Syros Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SYRSSyros Pharmaceuticals4.1204 of 5 stars$0.00-91.3%$3.33+128,105.1%-100.0%$1.65M$386K0.00120PBMPsyence Biomedical0.9752 of 5 stars$4.90-5.8%N/A-97.5%$2.96MN/A0.00N/ASPRBSpruce Biosciences2.0491 of 5 stars$0.07-3.3%$1.75+2,400.0%-83.3%$2.96M$4.91M-0.0720Gap UpAFMDAffimed2.837 of 5 stars$0.18-34.9%$3.62+1,895.9%-96.4%$2.92M$877K0.00200News CoverageGap DownHigh Trading VolumePRFXPainReform0.5305 of 5 stars$1.43+2.1%N/A-31.7%$2.82MN/A0.004JAGXJaguar Animal Health2.544 of 5 stars$2.54-1.6%$60.00+2,262.2%-97.6%$2.63M$11.69M0.0050ADTXAditxtN/A$1.12-8.9%N/A-100.0%$2.61M$130K0.0060News CoverageGap DownHigh Trading VolumeONCOOnconetix0.5651 of 5 stars$4.31-7.3%N/A-99.1%$2.48M$2.52M0.0012News CoverageTrading HaltedPTNPalatin TechnologiesN/A$0.09-44.6%N/AN/A$2.45M$350K-0.0630Gap DownHigh Trading VolumeAWHAspira Women's Health0.963 of 5 stars$0.08-12.5%$5.50+6,607.3%-94.9%$2.44M$9.18M-0.07110News CoverageHigh Trading VolumeALZNAlzamend Neuro2.7897 of 5 stars$2.88-2.0%$180.00+6,150.0%-90.6%$2.35MN/A0.004 Related Companies and Tools Related Companies PBM Alternatives SPRB Alternatives AFMD Alternatives PRFX Alternatives JAGX Alternatives ADTX Alternatives ONCO Alternatives PTN Alternatives AWH Alternatives ALZN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SYRS) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCentral Banks Are Hoarding Gold – Should You?The AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredAll New Social Security Numbers coming July 23?To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Syros Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
